CDC-RFA-JG-24-0131: Public Health Partnerships to Accelerate Prevention and Control of Infectious Diseases and Emerging Public Health Threats in China and Globally
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control-GHC notices from 2024.
Centers for Disease Control-GHC offered grants to any type of organization. It expected to make about 3 awards worth $5.0 million in total. Applications closed on June 10, 2024.
From the official notice on Grants.gov, last changed May 22, 2024. Checked November 7, 2026.
- Total funding$5.0 million
- Expected awards3
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 10, 2024 |
|---|---|
| Deadline | June 10, 2024 |
| Archived by Grants.gov | September 27, 2024 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
This is a fully competitive NOFO and eligibility is unrestricted, meaning any and all types of organizations and entities are eligible to apply. In addition, as may be required by host country laws, applicants are expected to comply with and document that they have satisfied all regulatory requirements of their governing entities that could otherwise compromise the integrity and resources provided by this program or hinder the performance of expected activities under this award. Applicants must also meet the criteria in CDC's review of risk posed by applicants to be eligible to receive funds under this NOFO. The Approximate Total Fiscal Year Funding/Average Year One Award Amount/Approximate Average Award amount for this NOFO is $1,000,000 for combined core components (Components 1-3). CDC will consider any application requesting an award higher than this amount as non-responsive, and it will receive no further review. Late submissions will be determined non-responsive unless a request for extension is approved following the procedure outlined in “Other Submission Requirements, Paper Submission”. Please see “Application and Submission Information” and “Submission Dates and Times” for the application deadline date. Please also see “Other Submission Requirements” for information on technical difficulties and paper submission. All requests to submit a paper application must be received at least three calendar days prior to the application deadline. CDC reserves the right to determine an application non-responsive as part of the Phase I review if the application does not respond to and falls outside the published scope of the NOFO as set out in the Background and CDC Project Description sub-sections within the Funding Opportunity Description section of this NOFO. CDC reserves the right to determine an application non-responsive if the Project Narrative file exceeds the 30-page limit. Although not required, the following four administrative materials may be included in the Project Narrative file and will not count toward the 30-page limit: 1) Table of Contents, 2) Cover or Title Page, 3) Non-Disclosure Statement, and 4) Acronym or Abbreviation List. All other content included in the Project Narrative file will count toward the 30-page limit.
Is this a realistic fit?
- Most of the program's money (49% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
This 5-year project’s purpose is to continue collaboration with counterparts in China to reduce the threat of infectious disease transmission, in China, the U.S. and the world. This collaboration contributes to enhancing the technical collaboration, scientific exchange, and effective communication to promote health through trusted and robust partnerships between U.S. CDC and counterparts in China. The program has three broad goals: 1) strengthen public health systems and workforce capacity, 2) decrease the burden of TB, and 3) reduce influenza morbidity and mortality and enhance preparedness for pandemic threats. Activities may include joint investigations and monitoring of disease outbreaks, piloting innovative public health interventions, translating programmatic success to practice and policy, working in third countries to jointly respond to a public health emergency, and promoting rapid and transparent dissemination of public health data. This collaboration strives to leverage the expertise in China to share knowledge and evidence-based science for a bi-lateral exchange that mutually benefits the U.S. and China. By identifying governmental, non-governmental, multilateral, and private sector organizations in China, the partnership builds sustainable expertise and capacity in global health security and public health systems. Depending on funding availability and priorities, the specific infectious disease entities to be addressed can change over the period of performance.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-JG-24-0131 still open?
No. It closed on June 10, 2024. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Public Health Partnerships to Accelerate Prevention and Control of Infectious Diseases and Emerging Public Health Threats in China and Globally?
Centers for Disease Control-GHC accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Public Health Partnerships to Accelerate Prevention and Control of Infectious Diseases and Emerging Public Health Threats in China and Globally?
Closed June 10, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $5.0 million in total across about 3 awards.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before?
The largest recipients over five fiscal years were African Field Epidemiology Network LTD, The Task Force for Global Health, Inc., World Health Organization, Somalia. The program made 306 awards worth $1.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)